Lundbeck and Otsuka's Antipsychotic Drug Rexulti Fails Two Bipolar Phase III Trials - BioSpace

Lundbeck and Otsuka's Antipsychotic Drug Rexulti Fails Two Bipolar Phase III Trials  BioSpaceDenmark's H. Lundbeck and Japan's Otsuka Pharmaceutical announced that their brexpiprazole failed to meet its primary endpoint in two Phase III clinical trials ...